Enabling
Advanced
Bioprocessing
Innovative solutions that
challenge the status quo
Capabilities Catalog
Bioprocessing
solutions built to
empower your
success
Since 1981, Repligen has been a
trusted partner to biopharmaceutical
manufacturers, driving progress
through innovative, high-value
bioprocessing solutions.
We understand the challenges you
face—reducing production time,
lowering costs, improving yields,
and ensuring top-tier product
quality. That’s why our cutting-edge
technologies and flexible solutions
are designed to meet your specific
needs at every critical stage of
biologic drug production.
Repligen redefines what is possible
in bioprocessing by delivering
innovative tools and expert guidance
that help you streamline workflows,
accelerate process development,
and achieve optimal results in
both clinical and commercial
manufacturing. Whether you’re
scaling up or fine-tuning, our
solutions are built to empower
your success.
Contents
Modalities
Workflow Capabilities and Solutions
12
Global Manufacturing Network
14
XCell® ATF Systems
16
KrosFlo® KPS TFF Systems
18
KrosFlo® TFDF® Systems
20
Upstream Process Analytical Technology
22
Cell Culture Supplements
24
KRM® Chromatography Systems
26
OPUS® Pre-packed Chromatography Columns
28
Ligands and AVIPure® Affinity Resins
30
KrosFlo® KTF+ TFF Systems
32
KrosFlo® RS TFF Systems
34
KrosFlo® KR2i, KMPi, and FS TFF Systems
36
KrosFlo® RPM® TFF Systems
38
Spectrum® Hollow Fiber Filters and TangenX® TFF Cassettes
40
Downstream Process Analytical Technology
42
ProConnex® Fluid Management Solutions
44
ProConnex® Single-Use Valve Technologies
46
ProConnex® MixOne CB-X and RG-X Systems
48
Metenova® Stainless Steel Mixers
50
Service Plans
52
Our Team
54
Sustainability
55
Repligen Enabling Advanced Bioprocessing
Antibodies and proteins
• Monoclonal antibodies: A cornerstone of biologic drug development, mAbs require
scalable, high-yield processes that maintain product quality and consistency of
mabs production.
• Antibody-drug conjugates (ADCs): By combining targeted antibody delivery with
potent cytotoxins, ADCs demand precise upstream and downstream production
control to ensure drug efficacy and require contained, aseptic processing to ensure
operator safety.
• Antibody fragments: Smaller and highly specific, antibody fragments call for
flexible purification and formulation approaches that preserve functionality.
• Bispecific antibodies: With dual-targeting capabilities, bispecifics introduce added
complexity in expression system and purification, requiring highly optimized
process solutions.
• Recombinant proteins: A diverse and rapidly evolving modality, recombinant
proteins benefit from adaptable workflows that support a wide range of molecular
formats and applications.
Viral vectors
• Adeno-associated virus (AAV): A key viral vector in gene therapy, AAV use is
expanding from rare disease applications to more common conditions, requiring
scalable, high-yield production processes that maintain quality while keeping drug
costs affordable.
• Lentivirus: A major viral vector platform used for both in vivo and ex vivo therapies,
lentivirus requires production methods that preserve its shear-sensitive nature
while ensuring consistent, high-yield, and safe products.
Enabling a new generation of
therapeutics
From established biologics to emerging platforms, today’s therapeutic modalities
are transforming disease treatment.
Repligen solutions are designed to help you overcome process development and
manufacturing challenges and support the production of innovative therapies
across a broad range of modalities, powering precision oncology, cell and gene
therapies, and more.
Cell therapy
• Induced pluripotent stem cells (iPSCs), T cells, CAR T-cells, natural killer cells, and
mesenchymal stem cells: In cell therapy, cells must be selected, modified, and
expanded, but the buildup of toxic metabolites can inhibit this process. Integration of
perfusion culture into the bioreactor can help to intensify potent cells and generate
more doses per batch.
• Extracellular vesicles (EV) and exosomes: EVs and exosomes are promising cell-free
therapies, but scaling up their production with consistent quality is challenging.
Perfusion systems help drive efficiency by removing waste, maintaining EV quality,
and continuously concentrating EVs.
Nucleic acid therapeutics
• Messenger RNA (mRNA): mRNA therapeutics demand precise in vitro transcription
processes and effective dsRNA removal to ensure stability and efficacy.
• Plasmid DNA (pDNA): A critical starting material for many advanced therapies, pDNA
production requires high-purity yields and scalable manufacturing workflows.
Whether you’re scaling up an established platform or developing new molecules, Repligen
provides bioprocessing tools, technologies, and support to help you drive progress, improve
process performance, and deliver impactful therapies.
Repligen Enabling Advanced Bioprocessing
Supporting scalable solutions for a
cornerstone modality
Monoclonal antibodies
Monoclonal antibodies (mAbs) remain one of the most widely used and successful
therapeutic modalities, demanding processes that deliver exceptional yield, purity, and
consistency at every scale. As programs move from early development to clinical and
commercial manufacturing, process intensification, robustness, and operational flexibility
become critical to meeting accelerating timelines and market needs.
Repligen supports mAb developers with end‑to‑end bioprocessing solutions engineered
to simplify complex workflows, reduce bottlenecks, and help teams scale confidently. Our
technologies are designed to keep your processes moving, empowering you to optimize
upstream productivity, streamline downstream purification, and achieve critical quality
attributes (CQAs).
Whether you’re optimizing an existing process or building a next-generation platform,
we provide the tools and expertise to power efficient, reliable mAb production.
Key capabilities:
• Proven technologies that scale seamlessly from bench to commercial production
• Consistent, high-quality output with all CQAs meeting acceptance criteria
• Integrated upstream-to-downstream support for a unified, streamlined process
• Experts dedicated to helping you solve challenges at any stage of product
development
Antibody−drug conjugates
Antibody−drug conjugates (ADCs) represent a promising therapeutic modality,
delivering targeted therapies directly to cancerous cells. However, ADC development
is a complex, multi-step process that demands exceptional control. Manufacturers
must manage the potency of the payloads, minimize operator exposure to cytotoxins,
maintain consistent drug-to-antibody ratios across batches, and ensure product efficacy
and safety by meeting the acceptance criteria of CQAs.
From early-stage development to commercial production, Repligen offers integrated
solutions and closed system connectivity across the entire workflow, including
antibody production, conjugation, drug-linker preparation, and ADC formulation.
Key capabilities:
• Solutions designed for drugs with high potency and toxicity, and closed processing
to protect operators and facilities
• Flexible, single-use technologies that simplify validation and reduce contamination
risk
• Scalable tools that adapt to program needs, from R&D to commercial manufacturing
• Expertise spanning antibody manufacturing, conjugation optimization, purification,
and final formulation
Repligen Enabling Advanced Bioprocessing
Powering cell and gene therapy
manufacturing with purpose-built
bioprocess solutions
Cell and gene therapies are reshaping the future of medicine, delivering
unprecedented treatment possibilities and life-changing outcomes. From cell-
based therapeutics to viral vector–driven gene delivery, Repligen provides flexible,
purpose-built bioprocessing solutions that streamline development, reduce risk,
and enable confident scalability from early development through commercial
manufacturing.
Cell therapy
Cell therapies, including ex vivo autologous and allogeneic approaches using T cells, stem
cells, iPSCs, and engineered cell modalities, as well as in vivo cell therapies enabled by
viral vector–mediated gene modification, require manufacturing processes that preserve
potent cell viability, maximize productivity, and meet rigorous quality and regulatory
standards.
Repligen solutions are designed to simplify, intensify, and scale cell therapy workflows.
Key capabilities:
• Process intensification with integrated perfusion to increase viable, potent cell
density and expand productive cultures
• Continuous harvest and clarification to maximize recovery of sensitive cell
populations
• Low-shear, low hold-up volume downstream technologies to maintain cell health and
product integrity
• Closed, single-use fluid management systems to support regulatory compliance and
reduce contamination risk
• Hands-on process development and implementation support from experienced cell
therapy specialists
• Process analytical technology to generate actionable data and enable accurate scale-
up predictions
Gene therapy
Gene therapy relies on viral vectors such as adeno-associated virus (AAV) and lentivirus,
as well as emerging modalities such as exosomes—all of which demand robust, scalable,
and highly consistent manufacturing processes.
Repligen supports gene therapy innovators with advanced bioprocessing tools that
improve yield, recovery, and workflow efficiency across viral vector production.
Key capabilities:
• Integrated perfusion and clarification strategies to reduce process complexity and
increase productivity
• Scalable bioprocessing solutions for complex upstream and downstream viral vector
workflows
• Continuous harvest technologies to improve vector capture and overall process yield
• Low-shear downstream systems that protect viral vector integrity during purification
• Single-use, closed-system solutions to support regulatory compliance and minimize
contamination risk
• Expert guidance from leaders in viral vector process development
• High-throughput resin screening to accelerate purification method development
10
Repligen Enabling Advanced Bioprocessing
Innovating for the future of
emerging modalities
Nucleic acid therapeutics
Since the global success of messenger RNA (mRNA) vaccines, new possibilities for nucleic
acid therapeutics have emerged at the forefront of biopharmaceutical innovation.
Modalities such as mRNA, small interfering RNA (siRNA), plasmid DNA (pDNA), and
oligonucleotides hold immense potential for diverse clinical applications, from infectious
disease to cancer treatment.
As with any modality, the development of these therapeutics relies on precise,
reproducible bioprocesses to deliver high-quality material at scale. Manufacturers face
numerous challenges, including preserving the stability of fragile nucleic acids, removing
closely related impurities, ensuring efficient and targeted delivery, and maximizing
efficacy while reducing the immunogenicity of the resulting therapeutics. As these
platforms mature, the demand continues to grow for nucleic acid manufacturing to
move quickly from development to commercial production without compromising purity,
consistency, or regulatory compliance.
Repligen provides flexible, scalable bioprocessing solutions that help innovators build
robust nucleic acid manufacturing workflows and solve today’s production challenges.
Key capabilities:
• Fully scalable chromatography and tangential flow filtration (TFF) equipment designed
with minimal shear and low hold-up volume performance
• Simplified manufacturing process with microfiltration TFF
• Simple, scalable solutions specifically designed for the removal of immunogenic
dsRNA byproducts from mRNA therapeutics
• Pre-packed chromatography columns for purification and process consistency
• In-line and online process analytical technologies to monitor CQAs
11
12
Repligen Enabling Advanced Bioprocessing
Empowering productivity and facility
efficiency in bioprocessing
13
Repligen products across the bioprocessing workflow
14
Repligen Enabling Advanced Bioprocessing
Ensure product availability with
manufacturing redundancy and
a secure supply chain
Learn more about our global locations
Corporate Headquarters
(Waltham, MA)
15
Global network designed to meet our customers’ needs
Headquarters
Waltham, MA (HQ)
Manufacturing Sites - United States
Anaheim, CA
Irving, TX
Auburn, MA
Lebanon, NH
Bridgewater, NJ
Marlborough, MA
Clifton Park, NY
Rancho Dominguez, CA
Hopkinton, MA
Manufacturing Sites - Europe
Breda, The Netherlands
Tallinn, Estonia
Lund, Sweden
Mölndal, Sweden
Waterford, Ireland
Ravensburg, Germany
Asia-Pacific Commercial Offices
Bangalore, India
Shiga, Japan
Gyeonggi-do, Korea
Singapore
Shanghai, China
Multi-site
Manufacturing
Safety Stock
Management Program
Secure Raw Material
Supply Chains
Complete Regulatory
Support Packages
Hands-on Service
16
Repligen Enabling Advanced Bioprocessing
Increase yield and improve efficiency
with process intensification
XCell® ATF Systems
Learn more about XCell® ATF Systems
XCell® ATF Systems enable continuous, intensified bioprocessing using Alternating Tangential Flow
(ATF) technology.
• XCell ATF Devices use alternating bidirectional flow that generates a backflush action that
cleans the filter, minimizing clogging and fouling.
• XCell ATF Controllers provide precise control, maintaining flow rates and monitoring filter
health to enable up to 60 days of continuous perfusion without filter changeout.
Intensified processes using XCell ATF Systems optimize space-time yield, achieving higher viable
cell densities in smaller bioreactors, reducing facility footprint, and significantly increasing overall
productivity and yield from process scale to commercial scale.
17
UPSTREAM
Why process intensification?
Process intensification improves upstream biomanufacturing by boosting
productivity and reducing cost of goods. Compared to fed-batch, perfusion
processes with XCell® ATF Technology deliver 5 – 10X greater volumetric
productivity, shorten production timelines by 15 – 30 days, and reduce
upstream cost of goods by up to 24%1.
1. Repligen (2025) From Fed-Batch to Perfusion: Unlocking ROI and Capacity in Monoclonal Antibody
Manufacturing. [White paper] BioProcess International.
18
Repligen Enabling Advanced Bioprocessing
Enable high-density cell culture with
TFF-based perfusion
KrosFlo® KPS Tangential Flow Filtration (TFF) Systems
KrosFlo® KPS Systems are engineered
for cell culture perfusion operations,
delivering a broad range of flow rates,
robust automation, and single-use
flexibility for process development
through manufacturing. Built on
decades of tangential flow filtration
(TFF) expertise, KrosFlo KPS systems
are highly configurable combining
operational flexibility, gentle cell
culture process handling, and scalable
performance within intensified
upstream workflows.
To unlock the full potential of the
KrosFlo KPS System, pair it with
Spectrum® Hollow Fiber Filters—
purpose-built for reliable cell retention
in upstream perfusion. Engineered for
seamless integration, Spectrum® filters
deliver exceptional viability, low-shear
handling, and consistent performance
even at high cell densities. Together,
they form a robust, closed-loop TFF
solution that supports high product
yield, and scalable operation from
development through production.
Learn more about KrosFlo® KPS Systems
19
UPSTREAM
20
Repligen Enabling Advanced Bioprocessing
Simplify and intensify
viral vector bioprocessing
KrosFlo® TFDF® Systems
Learn more about KrosFlo® TFDF® Systems
KrosFlo® TFDF® Technology
The KrosFlo® Tangential Flow Depth
Filtration® (TFDF®) Systems simplify and
improve viral vector bioproduction by
increasing viable cell density, productivity,
yield, and recovery for a more robust and
efficient process. This game-changing
technology combines the benefits of
tangential flow filtration (TFF) with the
efficiency of depth filtration (DF) to deliver
a scalable, high-performance solution for
applications such as perfusion, continuous
viral particle harvest, and clarification.
ProConnex® TFDF® Flow Paths
ProConnex® TFDF® Flow Paths are ready-
to-use, closed single-use assemblies
that arrive gamma-irradiated, dry, and
preservative-free. Requiring zero flushing,
each assembly includes a TFDF filter, a
disposable pump head, integrated sensors,
tubing, and aseptic connectors, ensuring
seamless set-up and sterile operation.